Clinical Trial Update: Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating radiation therapy with sorafenib for hepatocellular carcinoma resistant to transarterial chemoembolization has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 1 | Status: WITHDRAWN